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Abstract: Lopinavir/ritonavir (LPV/r) is considered by many as the first choice protease 
inhibitor (PI) for children. This co-formulation avoids the need for children to take ritonavir 
separately to “boost” the levels of lopinavir. LPV/r has high virologic potency, an excellent 
toxicity profile and a high barrier to the development of viral resistance. However, LPV/r has 
poor tolerability of the oral suspension (due to the poor taste of ritonavir), difficult dosing 
requirements and metabolic side effects, especially hyperlipidemia. The new tablet low-dose 
formulation (100/25 mg) may allow more convenient antiretroviral treatment in children. Novel 
strategies of LPV/r in childhood could maximize its advantages. For example, infants infected 
with HIV despite single dose Nevirapine after birth need effective combination antiretroviral 
treatment. This can be given using a higher dose of LPV/r with therapeutic drug monitoring. 
Other novel uses include once daily LPV/r regimens in older children and adolescents and 
lower doses of LPV/r in certain populations, which may decrease hyperlipidemia. Heavily 
pre-treated children might benefit from a double PI/r regimen which includes LPV/r. The high 
potency of LPV/r needs to be balanced with convenient regimens, to enhance adherence and 
decrease toxicity whenever possible. The aim of this review is to discuss the rationale behind 
these novel strategies of LPV/r use in pediatric antiretroviral treatment as well as their results 
and limitations.
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Introduction
Since the emergence of the HIV/AIDS pandemic children worldwide have suffered 
its devastating consequences. In 2007, UNAIDS estimated that 2.1 million children 
under 15 years old were living with HIV/AIDS, 420,000 children acquired the infec-
tion and 290,000 died of AIDS during this year.1,2
Without treatment, many HIV-infected children will die during the first year of 
life and half will not survive to their tenth birthday. Combination treatment (with 3 
or more antiretroviral drugs) has dramatically changed the outlook for children with 
HIV infection, producing a marked decrease in mortality.3 This outstanding outcome 
has been particularly noticeable since the introduction of the protease inhibitors (PI) 
as part of Highly Active Antiretroviral Therapy (HAART) in 1997.4–6
The PIs are a class of antiretroviral drug that bind competitively to the viral protease 
enzyme that inhibits the cleavage of the gag-pol polyprotein. This results in production 
of immature non-infectious viral particles, and prevents subsequent cellular infection. 
Currently, 9 PIs are approved for the treatment of HIV-infection, 7 of which are approved HIV/AIDS - Research and Palliative Care 2010:2 60
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for use in children and have pediatric drug formulations. 
Most PIs are “boosted” by low-dose ritonavir (an extremely 
potent inhibitor of cytochrome P450 3A4 activity), which 
prevents metabolism of the second PI, leading to high levels. 
Boosted atazanavir, fosamprenavir, darunavir and saquinavir 
have comparable efficacy with boosted lopinavir in adults, 
but there are few pediatric data.9,10
There is much variability among pediatricians about what 
HAART to prescribe for children. Current recommendations 
suggest combinations of two nucleoside reverse transcriptase 
inhibitors (NRTIs) plus either a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) or a PI.9 The choice of whether to 
use a PI or an NNRTI in children is still unclear and is being 
addressed in the PENPACT 1 study (a 4-year randomized 
trial which finished in 2009).7,8
If a PI-based regimen is selected in children, lopinavir/
ritonavir (LPV/r) is the preferred PI as most pediatric data are 
available for this PI. Numerous adult and pediatric studies have 
shown a high virologic potency, an excellent toxicity profile 
and a high barrier to develop resistance.9 However, LPV/r has 
several limitations, such as poor tolerability of the oral suspen-
sion, difficult dosing requirements and undesirable metabolic 
side effects, especially hyperlipidemia which has unknown 
consequences as the child grows into adulthood.10–12
Children and infants provide unique challenges for anti-
retroviral treatment. Firstly, they have higher viral loads than 
adults, due to an immature immune system that is unable to 
control viral replication. Secondly, accurate drug dosing is 
problematic, particularly in small children for whom lack 
of pharmacokinetic data and pediatric formulations reduce 
the availability of effective antiretroviral therapy (ART) and 
may predispose to sub-therapeutic drug levels. Finally, the 
need for a caregiver to administer the drugs to a child makes 
it hard to achieve the required 95% adherence throughout 
childhood. For all these reasons, data derived from adult 
studies are not entirely applicable to children and specific 
pediatric trials have to be conducted.4
In industrialized settings HIV infection is increasingly 
considered as a chronic disease. Multiple initiatives have 
aimed to simplify treatment and enhance adherence, as treat-
ment may have to be lifelong. This is particularly relevant in 
pediatrics due to the longer course of the infection. Several 
studies have examined new therapeutic approaches such as 
monotherapy with high efficacy ART, low-dose combina-
tions or dual PI regimens. LPV/r has been used in this way 
and the aim of this review is to discuss the rational behind 
these novel strategies of LPV/r use in pediatric antiretroviral 
treatment as well as their results and limitations.
Lopinavir/ritonavir in pediatric 
antiretroviral treatment
LPV/r was the sixth PI approved by the Food and Drug 
Administration (FDA). It is the only PI co-formulated as 
a fixed combination of lopinavir (LPV , initially known as 
ABT-378) and ritonavir (RTV). Ritonavir inhibits the hepatic 
metabolism of lopinavir increasing its plasma concentra-
tion.13 Ritonavir can be given separately to “boost” other 
PIs. However ritonavir suspension has an extremely poor 
taste and the capsule is large, making adherence in children 
extremely difficult. The co-formulation of RTV with LPV 
avoids some of these issues, although the suspension still 
has a poor taste.
LPV/r soft-gelatine capsule and oral solution were the 
first formulations approved for use in children. In March 
2006, the capsule was replaced with a tablet formulation 
that used proprietary melt-extrusion technology. This offers 
several advantages over the capsule formulation, such as, 
lower pill burden, fewer gastrointestinal adverse effects and 
easier storage requirement (no need for refrigeration). In 
November 2007, the FDA approved a low strength tablet 
formulation (100/25 mg) for the use in children (available in 
the EU since 2008).14,15 The major disadvantage of the new 
tablet formulation is that the tablets can not be cut or crushed, 
as bioavailability is lost. This can make accurate dosing in 
children difficult. For example a child requiring 250/62.5 mg 
of LPV/r twice daily may either be given 200/50 mg in tablet 
form plus 50/12.5 mg as suspension twice daily, or 200/50 mg 
in tablet form in the morning and 300/75 mg in tablet form 
in the evening. Neither of these regimens is ideal and the 
pediatrician and caregivers will have to discuss which is most 
likely to achieve good adherence.
Currently several dosage forms of LPV/r are available for 
the treatment of pediatric HIV-infection (see Tables 1 and 2). 
A brief summary of the main pharmacokinetic and pharma-
codynamic properties of LPV/r is shown in Table 3.
New strategies on the use of LPV/r 
in pediatric antiretroviral treatment
The limitations observed with the long-term use of LPV/r in 
children have impelled the scientific community to explore 
Table 1 Dosage forms of LPV/ra
•  Oral solution containing lopinavir 80 mg/mL and ritonavir 20 mg/mL
•  Film-coated tablets containing lopinavir 200 mg and ritonavir 50 mg
•  Film-coated tablets containing lopinavir 100 mg and ritonavir 25 mg
aThe capsule was withdrawn in 2008.HIV/AIDS - Research and Palliative Care 2010:2 61
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new ways to benefit from the high antiviral potency of LPV/r 
minimizing its disadvantages.
Use of LPV/r in infants
The risk of disease progression in HIV is inversely corre-
lated with the age of the child, with the youngest children 
at greatest risk of rapid progression.16,17 Currently, both 
European and American guidelines recommend that anti-
retroviral treatment should be started in every HIV infected 
infant under 12 months of age regardless of immune status 
or viral load.18 This recommendation follows a 4-fold reduc-
tion in HIV progression/mortality among infants starting 
HAART at less than 3 months of age compared to later, 
in both a large cohort meta-analysis and a randomized 
controlled trial.19,20
This is particularly relevant in resource-limited settings 
where most children with HIV/AIDS live. The mortality rate 
of HIV-infected children in developing countries is 45% to 
59% by 2 years of age compared with 10% to 20% in the 
EU and the US but early ART among infants between 6 to 
12 weeks with CD4% 25 has been associated with a reduc-
tion in mortality of 76%.19,21,22
Babies may be infected with HIV despite attempts 
to prevent mother-to-child transmission. In resource-
limited settings these infants will often have been given 
the NNRTI nevirapine (NVP). Those infants who become 
infected despite nevirapine use have a high risk of NNRTI 
resistance, raising concerns about the efficacy of NNRTI-
based regimens within the first year of life in NVP-exposed 
infants. The efficacy of highly active agents other than 
NVP to treat very young infants, such as PIs, needed to 
be assessed.23
LPV/r could thus be considered as one of the first-line 
agent choices for early antiretroviral treatment because of 
its liquid formulation.24
Nelfinavir was the first PI used extensively in children. 
High doses were needed to achieve effective drug levels in 
infants and there was great intersubject variation. Poor long-
term viral suppression was reported with nelfinavir given in 
the first 3 months of life (11 out of 16 infants experienced 
virological failure and 30% developed resistance).25
LPV/r was initially approved in Europe for children older 
than 2 years and it has become the first choice PI in children.26 
However young infants have a higher apparent clearance 
Table 2 Pediatric dosing scheme for LPV/r39,48
Children aged 14 days to 6 months 16/4 mg/kg or 300/75 mg/m2 
twice daily
Children aged 6 months to 12 years
  • Weight: 7 to 15 kg 
  • Weight: 15 to 40 kg
12/3 mg/kg or 230/57.5 mg/m2 
twice daily
10/2.5 mg/kg or 230/57.5 mg/m2 
twice daily (max dose of 
400/100 mg twice daily)
Children aged 6 months to 18 years with co-administration of EFV, 
NVP, NFV or (fos)amprenavir in either naïve or treatment-experienced 
patients
  • Weight: 15 kg 13/3.25 mg/kg twice daily
  • Weight: 15 kg 11/2.75 mg/kg twice daily with-
out exceeding the adult dose
Abbreviations: LPV/r, lopinavir/ritonavir; EFV, efavirenz; NVP, nevirapine; NFV, 
nelfinavir.
Table 3 Pharmacology and pharmacokinetics of LPV/r14,48,49
Absorption Absorption of LPV/r liquid formulation is affected by 
the presence of food (the AUC and the Cmax of LPV 
increased by 130% and 56% respectively when given 
with a high-fat meal compared with a fasting state).
LPV/r tablets may be taken with or without food as 
long as the tablets are swallowed whole, without being 
chewed, crushed or broken.
Cmax of LPV of 9.8 ± 3.7 µg/mL 4 hours after the intake 
of the drug have been reported in adults after multiple 
dosing with 400/100 mg twice daily during 3–4 weeks.
Minimum concentration within a dosing interval (12 h) 
was 5.5 ± 2.7 µg/mL Minimum effective concentration 
in treatment naïve adults has been established at 
1 µg/mL.
AUC during a 12 hour dosing interval was 92.6 ± 
36.7 µg*h/mL.
The absolute bioavailability of LPV/r has not been 
established in humans.
Distribution LPV is approximately 98%–99% bound to plasma 
  proteins (alpha-1-acid glycoprotein and albumin 
transport LPV).
LPV/r accumulates intracellularly. Intracellular/plasma 
concentration of 1.18 has been reported.
LPV is lipid soluble therefore penetrates the cerebro-
spinal fluid where a significant reduction of HIV viral 
load has been shown.
Metabolism LPV is extensively metabolized by the hepatic cyto-
chrome P450 system, almost exclusively by the CYP34 
and CY3A5 isoenzymes.
RTV is a potent CYP34 inhibitor and consequently 
increases plasma levels of LPV when the two drugs are 
co-administered.
RTV has been shown to induce metabolic enzymes, 
resulting in the induction of its own metabolism.
Elimination After administration of LPV/r, approximately 10.4% ± 
2.3% and 82.6% ± 2.5% of the administered dose can 
be found in urine and feces respectively after 8 days. 
Unchanged LPV accounted for nearly 2.2 and 19.8% of 
the administered dose in urine and feces, respectively. 
The apparent oral clearance of LPV is 5.98 ± 5.75 L/h.
Abbreviations: LPV/r, lopinavir/ritonavir; AUC, area under the curve; Cmax, maximum 
plasma concentration; LPV, lopinavir; RTV, ritonavir.HIV/AIDS - Research and Palliative Care 2010:2 62
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of drugs and altered absorption. Extrapolating the dosage 
schedule followed in older children could lead to potential 
toxicity and/or lower exposure in young infants to ART, with 
incomplete virological suppression and the subsequent risk 
of viral resistance.27
The different absorption and distribution of LPV/r in 
young children compared with older children was initially 
observed by Verweel et al in a retrospective cohort study 
of 23 children who underwent a 12-hour pharmacokinetic 
sampling for LPV . Children under 2 years of age had a sig-
nificantly lower Cmin and Cmax compared to children older 
than 2 years of age after receiving LPV/r 230/57.5 mg/m2 
twice daily. A dose increase by 37% resulted in an adequate 
LPV trough concentration in children younger than 2 years. 
Therefore a higher dose of 300/75 mg/m2 twice a day in 
children less than 2 years old was suggested.28 Chadwick 
et al investigated the pharmacokinetics, safety and efficacy of 
LPV/r plus two NRTIs in infants aged between 6 weeks and 
6 months in a prospective trial including 21 infants. Infants 
received LPV/r 300/75 mg/m2 twice daily and were followed 
for 24 weeks. LPV/r clearance was slightly higher than that 
observed in older children, but the median AUC-time curve 
0–12 h was similar to that seen in older children receiving 
230/57.5 mg/m2 of LPV/r. The trough levels stabilized after 
the first 2 weeks of the study, which according to the authors, 
could be explained by improved absorption of the drug, better 
technique of administration, dietary changes or variation in 
RTV oral clearance.24
A median decrease in HIV viral load (VL) of 3.13 
log10 copies/mLwas observed at week 24, but only 38% 
had an undetectable VL (400 copies/mL) at weeks 16 and 
24. The virological response at week 16 was not associated 
with the LPV/r exposure at week 2, but viral suppression 
improved over time during the study. One infant interrupted 
treatment within the first 2 weeks of the study because of 
vomiting. 14.3% of the infants experienced a grade 3 or 
higher adverse events (transient neutropenia) but all were 
asymptomatic and transient. The authors concluded that a 
twice-daily dose of 300/75 mg/m2 of LPV/r in infants under 
6 months gave a similar exposure to that reported in older 
children with favorable clinical and virological efficacy.24
Chadwick and colleagues also reported the use of LPV/
r-based regimens in infants less than 6 weeks of age in a 
prospective, phase I/II study. This included 10 infants with 
confirmed HIV-1 infection aged between 2 and 6 weeks who 
received 300/75 mg/m2 of LPV/r twice daily plus 2 NRTIs 
and were followed 24 weeks. The median LPV AUC of 
36.6 µg/mLwas significantly lower than that found in infants 
aged between 6 weeks and 6 months of age. The half-life of 
LPV was similar to that seen in older infants, so the authors 
postulated that reduced bioavailability of LPV could be the 
main cause for the lower LPV exposure rather than enhanced 
LPV metabolism. Altered absorption of LPV/r could be due 
to the food intake of the infants enrolled, though there was 
no correlation between the time and volume of formula milk 
received and LPV exposure in this study. The authors sug-
gested that the addition of other foods might enhance LPV 
bioavailability in this age group. This needs to be evaluated 
in larger trials. This is particularly important because most 
infants that might benefit from early ART also suffer con-
comitant food insecurity.27
The authors assessed that despite the lower peak and 
average LPV exposure observed, the LPV trough was similar 
to that reported in older infants and an excellent virological 
response was achieved. The long-term follow-up of these 
patients would help to determine the variations of LPV/r 
pharmacokinetics and its long-term efficacy.27
These initial studies suggest that LPV/r may be used in 
young infants, but if used therapeutic drug monitoring (TDM) 
should be always considered. Data from larger trials are needed 
to evaluate the impact that other factors (like genetics or race) 
might have on LPV/r exposure during the first months of life. 
An improvement in the palatability of the oral formulation 
of LPV/r is urgently needed if extensive use of this drug is 
recommended after the early diagnosis of the HIV infection. 
Otherwise, poor adherence with possible incomplete viral sup-
pression and resistance might happen early in life and make 
future antiretroviral treatment even more complex.
Monotherapy with LPV/r
The dramatic success of HAART has also brought important 
complications such as lipodystrophy, dyslipidemia or lactic 
acidosis. Complex dosing schedules with a high daily pill 
burden hinders the benefits of HAART and compromises its 
long-term use. Therefore, strategies like monotherapy with 
highly potent ART such as a boosted PI (PI/r) seemed an 
appealing way to enhance adherence and decrease complica-
tions. Single-drug antiretroviral therapy may be less toxic, 
easier to use and less costly while effectively maintaining 
long-term virological suppression and preserving future 
treatment options.29
Adult studies – LPV/r monotherapy 
after initial HAART
The use of LPV/r monotherapy as an NRTI-sparing treat-
ment simplification strategy in patients with sustained viral HIV/AIDS - Research and Palliative Care 2010:2 63
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suppression was evaluated by Moltó et al in a retrospective 
cohort of 51 adults; 95% of the patients who were followed 
until 48 weeks maintained viral suppression, with a sustained 
increase in CD4% cell counts and a significant decrease in 
triglyceride levels. The authors concluded that this treatment 
simplification approach was safe and effective in routine 
clinical practice, especially in those patients already receiv-
ing a LPV/r based regimen.30
Similar results were obtained in the OK04 study group 
in a randomized, open label, non-inferiority clinical trial in 
205 patients with suppressed viral replication on LPV/r plus 
2 NRTI. Patients were randomized to continue HAART or 
LPV/r monotherapy with the reintroduction of 2 NRTIs if 
virological rebound was observed. At week 48, the percent-
age of patients without therapeutic failure was 94% in the 
monotherapy arm versus 90% in the triple therapy group. 
The percentage of patients with HIV RNA 50 copies/mL 
at week 48 by intention-to-treat analysis was 85% in the 
monotherapy groups versus 90% in the HAART arm, with-
out statistically significant differences. Episodes of low 
level viremia were more common in patients receiving 
LPV/r monotherapy although the long-term significance 
of these “blips” is unknown. This study showed that LPV/r 
monotherapy (with reintroduction of NRTIs if needed) was 
non-inferior to conventional HAART.31
LPV/r monotherapy in ART-naïve  
adult patients
The use of LPV/r as monotherapy as initial therapy in adult 
patients was evaluated in the MONARK study;32 an open-
label, randomized, 96-week clinical trial which compare the 
efficacy of LPV/r monotherapy (n = 83) with LPV/r plus ZDV 
and 3TC (n = 53) as an initial treatment in naive patients with 
VL 100,000 copies/mL. LPV/r monotherapy showed lower 
rates of virological suppression; in an intent-to-treat analy-
sis 64% of the patients in the monotherapy group showed 
VL 50 copies/mL, whereas 75% of those on conventional 
HAART maintained viral suppression. In the on treatment 
analysis, there was a significant difference on the patients 
who achieved an undetectable VL in both groups (80% in 
LPV/r monotherapy vs 95% in the HAART group). Three 
patients in the monotherapy arm without virological suppres-
sion acquired new resistance mutations with modest impact 
on LPV susceptibility. This study did not support the use of 
LPV/r monotherapy in ART-naïve adult patients.
Recently Ghosn et al reported the 96-week follow-up 
of the MONARK study.33 By an intention-to-treat analysis, 
47% of those initially randomized to LPV/r monotherapy 
had sustained viral suppression (50 copies/mL). The 
occurrence of low-level viremia in some patients during 
follow-up, with the subsequent risk of drug resistance, has 
discouraged the use of LPV/r monotherapy in ART-naïve 
HIV-infected adults.
Pediatric studies
Antiretroviral treatment in children achieves less viral sup-
pression than in adults. Therefore, the use of LPV/r mono-
therapy in naïve children has been avoided and the potential 
role of LPV/r monotherapy in ART-experienced children 
with viral suppression evaluated with caution. A prospective 
clinical trial of the use of LPV/r monotherapy as maintenance 
in Thai children (aged between 2 and 28 years) after VL 
suppression is ongoing (HIV Netherlands Australia Thailand 
Research Collaboration). Results will not be available for 
some time. A Paediatric European Network for the Treatment 
of AIDS (PENTA) trial of LPV/r monotherapy after HAART 
is also planned. Meanwhile, based on the current evidence 
in adults, LPV/r monotherapy should be discouraged in 
children, particularly during the first years of life.
LPV/r once-daily regimens
Once-daily administration regimens could increase conve-
nience and adherence as LePrevost et al showed with abacavir 
(ABC) plus 3TC use in children.34 However, the efficacy of 
once-daily ART is highly dependent on the maintenance 
of inhibitory concentrations throughout the entire dosing 
interval.35
Adult studies
In treatment-naïve adults the administration of LPV/r in a 
single daily dose showed similar immunological and viro-
logical outcomes to the standard twice-daily regimen. Based 
on this experience, several studies have evaluated this new 
strategy with other drugs such as SQV/r in adult HIV-infected 
patients.36,37
Pediatric studies
In children, the change to a once-daily combination includ-
ing boosted atazanavir in extensively ART experienced-
children was associated with a significant risk of virological 
failure. Limited data are available about the use of other 
PIs, such as LPV/r, in a once-daily regimen. Pilot studies 
of once-daily LPV/r in children (dosed at 460/115 mg/m2) 
found similar pharmacokinetics to adult studies. How-
ever there was marked variation between individuals and 
studies; the observed median Cmin were just above the HIV/AIDS - Research and Palliative Care 2010:2 64
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minimal effective concentration and around 50% of patients 
showed trough levels below inhibitory levels. The new 
tablet formulation gave better drug levels and less varia-
tion (see Table 4).38
The use of LPV/r once daily is still not recommended 
in pediatric antiretroviral treatment guidelines because 
there is no evidence yet from large trials.39 A PENTA trial 
is planned to study this in more detail (PENTA 18).40 All 
the pediatric trials of once-daily LPV/r have not included 
children under 2 years old who have a more erratic LPV/r 
exposure. If LPV/r once daily is used in older children 
TDM should be carried out. Nevertheless, the advent of 
the tablet formulation of LPV/r, particularly the low-dose 
tablet, increases the feasibility of LPV/r once-daily regi-
mens in children.
Double boosted PI regimens
When planning salvage regimens for children failing on 
NRTI/NNRTI-based HAART; pediatricians are often faced 
with multiple resistance mutations and limited options. 
Furthermore, response to salvage treatment containing a 
single PI might be suboptimal if little efficacy remains in 
the NRTI component or if progressive toxicity is associated 
with continued used of NRTIs.41
Dual ritonavir-boosted PI (PI/r) regimens represent an 
option for salvage or maintenance therapy for patients with 
reverse transcriptase mutations or intolerance.42 Double PI/r 
have the advantage of the boosting effect of RTV on plasma 
levels of both PIs and in vitro data have shown a synergistic 
effect of saquinavir (SQV) when combined with LPV/r.43
The efficacy of dual boosted PI combination has been 
assed in few studies among children. The combination of 
LPV/r and saquinavir gave good virological responses, but 
was associated with increases in cholesterol. This combina-
tion is used in Thailand as an alternative for second line 
treatment in PI-naïve children who failed NRTIs/NNRTIs 
regimens, but the high pill burden makes adherence difficult 
(see Table 5).
Double boosted PI/r regimens should not be used alone in 
naïve patients with high viral loads because they have been 
shown insufficient to suppress viral replication. Landman 
et al reported 61 naïve HIV-infected adults who received 
fosamprenavir/atazanavir/RTV or saquinavir/atazanavir/
RTV; viral suppression was only achieved in 40% and 42% 
of patients respectively at week 16.44
However, the encouraging results in pre-treated children 
suggest that double PI/r regimens may be an effective and 
safe option for these children. However, they also carry a 
high pill burden, and thus adherence support is extremely 
important. The additional benefit that TDM could add to 
this strategy needs to be studied in more detail in children, 
because a dose reduction could reduce the frequency of 
metabolic side effects without compromising its efficacy. 
The new low-dose tablet formulation of LPV/r allows the 
possibility of double PI/r regimen with less toxicity and 
better acceptability.
Table 4 Summary of the pediatric studies on LPV/r once-daily regimens
Author Methods Results
Rosso et al50 21 HIV-infected ART-naïve children  
Dose of LPV/r 460/115 mg/m2 once daily as  
soft-gel capsules after 1 month of 
standard twice-daily therapy
Median Cmin 1.59 mg/L in the once daily group vs 7.90 mg/L in the twice daily group. 
Cmin inhibitory for wild-type virus (1.0 mg/L) in 4 out of 7 children in the once 
daily group 
No significant differences in the Cmax between groups
van der Lee et al51  19 HIV-1 infected ART-experienced children  
with VL  50 copies/mL for at least 6 months  
Dose of LPV/r 460/115 mg/m2 once daily as  
soft-gel capsules
Median Cmin 2.88 ± 3.74 mg/L, median Cmax 10.77 ± 2.90 mg/L,  
median AUC0–24 149.8 ± 58.8 h*mg/L – comparable to adults receiving 
800/200 mg of LPV/r once daily. 
Cmin inhibitory for wild-type virus (1.0 mg/L) in 47% children, less in 
younger children
la Porte et al52 7 pretreated children aged 5 to 15 years.  
Dose of LPV/r 460/115 mg/m2 once daily or  
230/57.5 mg/m2 twice daily as soft-gel capsules
Once daily 
Median C24 h = 3.4 mg/L 
Median Cmax = 13.5 mg/L  
Median  AUC0–24 = 214.6 h*mg/L 
Twice daily
Median C12 h = 5.7 mg/L  
Median Cmax = 9.8 mg/L  
Median   AUC12 h = 80.9 h*mg/L
van der Flier et al53 
 
 
 
 
15 HIV-1 infected children who had received  
at least 24 weeks of LPV/r treatment (with  
soft gel capsules) and had achieved virological 
suppression.  
Dose of LPV/r 460/115 mg/m2  
once daily as tablet formulation
Mean Cmin 3.1 ± 2.6 mg/mL, mean Cmax 14.8 ± 2.4 mg/L,  
mean AUC0–24 217.9 ± 44.9 mg/L*h 
LPV half-life = 5.8 ± 4.5 h; median time to maximum concentration = 5.8 h. 
Every child included in the study had an undetectable VL at week 24 of 
follow-up 
Abbreviations: LPV/r, lopinavir/ritonavir; Cmin, minimum plasma concentration; Cmax, maximum plasma concentration; PK, pharmacokinetic; AUC0–24, 24 h area under the plasma 
concentration-time curve; AUC12 h, 12 h area under the plasma concentration-time curve.HIV/AIDS - Research and Palliative Care 2010:2 65
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Low-dose LPV/r
The effect that different isoenzyme polymorphisms have 
on the pharmacokinetics of drugs such as efavirenz has 
raised the importance of genetic factors in determining 
the dosage of ART.45 Studies have looked at using LPV/r 
at reduced doses in certain ethnic groups.
Adult studies
Boyd et al showed a satisfactory response and adequate PK 
profile in Thai adults with a 50% reduction in the dose of 
indinavir/RTV . Lower doses of saquinavir/ritonavir (SQV/r) 
and LPV/r were also evaluated and a 70% dose of LPV/r is 
currently accepted for Thai adults.46
Pediatric studies
The desirable benefits of LPV/r lower doses such as cost 
reduction and decreased rates of metabolic side effects would 
be valuable in pediatric antiretroviral treatment. A pilot study 
of low-dose LPV/r conducted by Puthanakit et al included 24 
ART-naïve HIV-infected Thai children aged between 2 and 
18 years. Patients received 70% of the standard dose twice a 
day plus zidovudine (ZDV) and lamivudine (3TC). At week 
48, there were no statistically significant differences in CD4% 
or viral load between children receiving the standard dose and 
those in the low-dose arm. The AUC0–12 and the Ctrough were 
lower in the low-dose arm (by 29% and 31% respectively).47
This pilot study included a small number of patients, 
and a LPV/r dose-reduction is not yet recommended for PI-
experienced children or infants. However the relevance of 
pharmacogenetic aspects on dosage schedule is proven and 
the need to adapt guidelines to different settings warranted. 
This study also suggests that TDM should be considered 
in all children on LPV/r in order to find out if a lower dose 
could be used. The advent of the new low-dose LPV/r tablets 
encourages the development of reduced dose studies among 
children due to its improved palatability and easier storage 
requirements compared with the liquid formulation.
Conclusions
The benefits achieved with LPV/r-based therapies in HIV-
infected children outweighs the metabolic adverse effects 
observed with its prolonged used. Therefore, until other PIs 
develop child friendly formulations, LPV/r will be considered 
the first choice for PI in childhood. The new tablet low-dose 
Table 5 Summary of pediatric studies on double boosted PI regimens
Author Methods Results
Ananworanich et al54 HIV-NAT 017 group (1st study):  
20 heavily pretreated  
Thai children: dose 50 mg/kg BD SQV plus 
230/57.5 mg/m2 twice daily LPV/r  
(50% also received 3TC)
HIV RNA was suppressed 400 copies/mL in 80% of the children 
after 24 weeks of treatment. Median increase in CD4 counts = 6%
 
Cmin  
Median AUC0–12 
SQV 
39.4 mg/L 
1.4 mg/L*h
LPV 
5.9 mg/L 
118 mg/L*h
significant correlation between a Cmax 15 mg/L and an increase in 
cholesterol  levels
Kosalaraksa et al55 HIV-NAT 017 group (2nd study):  
50 Thai children: dual boosted combination 
of SQV/LPV/r (as above)  
after 48 weeks of follow-up
Median rise in CD4% = 9%, median decrease in HIV RNA viral load = 
2.8 log10 
Mean Cmin of both PIs exceeded therapeutic concentrations. 
10% of participants had virologic failure associated with poor  
adherence, none selected major PI mutations 
Median serum cholesterol and triglyceride increased significantly
Bunupuradah et al56 HIV-NAT 017 group (3rd study): 
96 week follow-up of the study conducted 
by Kosalarska et al (see above)
HIV RNA was suppressed below 400 copies/mL in 74% of the chil-
dren after 96 weeks 
20% of participants had virologic failure. Median increase in CD4 + 
count = 558 cells/mm3  
Total cholesterol and HDL increased significantly during the study, 
whereas triglycerides and not report any change in body shape. 
Both LPV and SQV Cmin were high and stable during follow-up
Robbins et al57 26 heavily experience-treated children and adolescents 
Dose: either LPV/r 400/100 mg/m2 twice daily without  
NNRTI or LPV/r 480/120 mg/m2 twice daily with  
concomitant NNRTI. If the LPV inhibitory quotient  
[Ctrough/IC50] was 15, SQV was added
Median maximal decrease in viral load at week 8 = 1.57 log10. 
However, the high dose was safe and well tolerated for up to 
48 weeks. The significant initial increase of cholesterol did not 
worsen during the study and no significant gastrointestinal problems 
were observed even when SQV was added.
Abbreviations: LPV/r, lopinavir/ritonavir; SQV, saquinavir;   AUC0–12, 12 h area under the plasma concentration-time curve; Cmin, minimum plasma concentration; Cmax, maximum 
plasma concentration; NRTIs/NNRTIs, nucleoside reverse transcriptase inhibitor/non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.HIV/AIDS - Research and Palliative Care 2010:2 66
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formulation increases the possibility for more convenient 
antiretroviral treatment in children.
Novel strategies of LPV/r use could maximize its 
  advantages during childhood; in infants a higher dosage with 
close TDM is a safe and effective option, especially in those 
exposed to single-dose NVP. Older children and adolescents 
could benefit from a once-daily LPV/r regimen and certain 
populations could be treated with lower doses if TDM can be 
guaranteed. Finally heavily pre-treated children might benefit 
from a double PI/r regimen which includes LPV/r.
All the previous approaches emphasize the lessons 
learnt with antiretroviral treatment in the past; high potency 
therapies need to be balanced with convenient regimens, to 
enhance adherence. No drug is effective if it is not taken and 
this is particularly challenging in children where both the 
patient and the caregiver needs to adhere to treatment.
Disclosures
The authors declare no conflicts of interest.
References
  1.  Homsy J, Moore D, Barasa A, Were W, Likicho C, Waiswa B, et al. 
Breastfeeding, Mother-to-Child HIV Transmission, and Mortality 
Among Infants Born to HIV-Infected Women on Highly Active Anti-
retroviral Therapy in Rural Uganda. J Acquir Immune Defic Syndr. 
2009. [Sep 30 Epub ahead of print].
  2.  Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness 
of antiretroviral therapy among HIV-infected children in sub-Saharan 
Africa. Lancet Infect Dis. 2008;8(8):477–489.
  3.  Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V , 
Thobakgale C, et al. Early virological suppression with three-class anti-
retroviral therapy in HIV-infected African infants. AIDS. 2008;22(11): 
1333–1343.
  4.  Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. 
International perspectives, progress, and future challenges of paediatric 
HIV infection. Lancet. 2007;370(9581):68–80.
  5.  Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, et al. 
Outcomes for human immunodeficiency virus-1-infected infants in 
the United kingdom and Republic of Ireland in the era of effective 
antiretroviral therapy. Pediatr Infect Dis J. 2006;25(5):420–426.
  6.  Harwell JI, Obaro SK. Antiretroviral therapy for children: substantial 
benefit but limited access. JAMA. 2006;296(3):330–331.
  7.  Vaclavikova J, Machala L, Stankova M, Linka M, Bruckova M, 
Vandasova J, et al. Response of HIV positive patients to the long-term sal-
vage therapy by lopinavir/ritonavir. J Clin Virol. 2005;33(4):319–323.
  8.  The devastating effects of HIV/AIDS on children.  Lancet. 
2006;368(9534):424.
  9.  Ramos J. Boosted protease inhibitors as a therapeutic option in the 
treatment of HIV-infected children. HIV Med. 2009;10(9):536–547.
10.  Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA 
guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5 
Suppl 2:61–86.
11.  Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose rito-
navir monotherapy on fasting serum lipid concentrations. HIV Med. 
2005;6(6):421–425.
12.  Rudin C, Burri M, Shen Y, Rode R, Nadal D. Long-term safety and 
effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in anti-
retroviral-experienced HIV-infected children. Pediatr Infect Dis J. 
2008;27(5):431–437.
13.  Saez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handels-
man E, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new 
protease inhibitor, in human immunodeficiency virus-infected children. 
Pediatr Infect Dis J. 2003;22(3):216–224.
14.  Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 
infection: a review. Ther Clin Risk Manag. 2008;4(5):1023–1033.
15.  Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, et al. The 
tablet formulation of lopinavir/ritonavir provides similar bioavailabil-
ity to the soft-gelatin capsule formulation with less pharmacokinetic 
variability and diminished food effect. J Acquir Immune Defic Syndr. 
2007;44(4):401–410.
16.  Newell ML, Patel D, Goetghebuer T, Thorne C. CD4 cell response 
to antiretroviral therapy in children with vertically acquired HIV 
infection: is it associated with age at initiation? J Infect Dis. 
2006;193(7):954–962.
17.  Verweel G, Saavedra-Lozano J, van Rossum AM, Ramilo O, de Groot R. 
Initiating highly active antiretroviral therapy in human immunodeficiency 
virus type 1-infected children in Europe and the United States: compar-
ing clinical practice to guidelines and literature evidence. Pediatr Infect 
Dis J. 2006;25(11):987–994.
18.  Riordan A, Bugembe T. Update on antiretroviral therapy. Arch Dis 
Child. 2009;94(1):70–74.
19.  Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. 
Early antiretroviral therapy and mortality among HIV-infected infants. 
N Engl J Med. 2008;359(21):2233–2244.
20.  Goetghebuer TH, Le Chenadec E. Early versus deferred highly active 
antiretroviral therapy in HIV infected infants: a European Collabora-
tive Cohort Study. 4th Dominique Dormont International Conference: 
Host-Pathogen Interactions in Chronic Infections; Paris, France, 13–15 
December, 2007.
21.  Obimbo EM, Mbori-Ngacha DA, Ochieng JO, Richardson BA, 
Otieno PA, Bosire R, et al. Predictors of early mortality in a cohort 
of human immunodeficiency virus type 1-infected African children. 
Pediatr Infect Dis J. 2004;23(6):536–543.
22.  Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, 
Seage GR 3rd, et al. Effect of combination therapy including protease 
inhibitors on mortality among children and adolescents infected with 
HIV-1. N Engl J Med. 2001;345(21):1522–1528.
23.  Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, 
et al. Response to antiretroviral therapy after a single, peripartum dose 
of nevirapine. N Engl J Med. 2007;356(2):135–147.
24.  Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, 
Rodman JH, et al. Pharmacokinetics, safety and efficacy of lopinavir/
ritonavir in infants less than 6 months of age: 24 week results. AIDS. 
2008;22(2):249–255.
25.  Hirt D, Urien S, Jullien V , Firtion G, Rey E, Pons G, et al. Age-related 
effects on nelfinavir and M8 pharmacokinetics: a population study with 
182 children. Antimicrob Agents Chemother. 2006;50(3):910–916.
26.  Kline MW, Rugina S, Ilie M, Matusa RF, Schweitzer AM, Calles NR, 
et al. Long-term follow-up of 414 HIV-infected Romanian children 
and adolescents receiving lopinavir/ritonavir-containing highly active 
antiretroviral therapy. Pediatrics. 2007;119(5):e1116–e1120.
27.  Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P, 
et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks 
of age: pharmacokinetics and 24-week safety and efficacy. Pediatr 
Infect Dis J. 2009;28(3):215–219.
28.  Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der 
Knaap LC, et al. Plasma concentrations of the HIV-protease inhibitor 
lopinavir are suboptimal in children aged 2 years and below. Antivir 
Ther. 2007;12(4):453–458.
29.  Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, 
et al. Protease inhibitor resistance analysis in the MONARK trial compar-
ing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus 
zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother. 
2009;53(7):2934–2939.
30.  Molto J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B. 
Lopinavir/ritonavir monotherapy as a simplification strategy in routine 
clinical practice. J Antimicrob Chemother. 2007;60(2):436–439.HIV/AIDS - Research and Palliative Care 2010:2
HIV/AIDS - Research and Palliative Care
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/hivaids---research-and-palliative-care-journal
HIV/AIDS - Research and Palliative Care is an international, peer-
reviewed open-access journal focusing on advances in research in HIV , 
its clinical progression and management options including antiviral 
treatment, palliative care and public healthcare policies to control 
viral spread. The journal welcomes original research, basic science, 
clinical & epidemiological studies, reviews & evaluations, expert 
opinion & commentary, case reports & extended reports. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
67
Lopinavir/ritonavir use in children Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
31.  Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J,   
Perez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopi-
navir-ritonavir and two nucleosides for maintenance therapy of HIV . 
AIDS. 2008;22(2):F1–F9.
32.  Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM,   
et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lami-
vudine in antiretroviral-naive HIV-infected patients. AIDS. 2008; 
22(3):385–393.
33.  Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, et al. 
Long-term (96-week) follow-up of antiretroviral-naive HIV-infected 
patients treated with first-line lopinavir/ritonavir monotherapy in the 
MONARK trial. HIV Med. 2009. [Aug 13 Epub ahead of print].
34.  LePrevost M, Green H, Flynn J, Head S, Clapson M, Lyall H, et al. 
Adherence and acceptability of once daily Lamivudine and abacavir in 
human immunodeficiency virus type-1 infected children. Pediatr Infect 
Dis J. 2006;25(6):533–537.
35.  Johnson MA, Gathe JC Jr, Podzamczer D, Molina JM, Naylor CT, 
Chiu YL, et al. A once-daily lopinavir/ritonavir-based regimen provides 
noninferior antiviral activity compared with a twice-daily regimen.   
J Acquir Immune Defic Syndr. 2006;43(2):153–160.
36.  Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, 
Prasithsirikul W, Kiertiburanakul S, et al. Long-term efficacy and safety 
of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther. 
2008;13(3):375–380.
37.  Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, 
et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-
naive HIV-positive patients: a 48-week randomized clinical trial.   
J Infect Dis. 2004;189(2):265–272.
38.  Macassa E, Delaugerre C, Teglas JP, Jullien V, Treluyer JM, 
Veber F, et al. Change to a once-daily combination including 
boosted atazanavir in HIV-1-infected children. Pediatr Infect Dis J. 
2006;25(9):809–814.
39.  Children. WGoATaMMoH-I. Guidelines for the Use of Antiretroviral 
Agents in Pediatric HIV Infection. February 23, 2009.
  40.  Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, 
Wintergerst U, et al. PENTA 2009 guidelines for the use of antiretroviral 
therapy in paediatric HIV-1 infection. HIV Med. 2009;10(10):591–613.
41.  Gupta RK, Gibb DM, Pillay D. Management of paediatric HIV-1 
resistance. Curr Opin Infect Dis. 2009;22(3):256–263.
42.  van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, 
Avihingsanon A, et al. Pharmacokinetics and short-term efficacy of a 
double-boosted protease inhibitor regimen in treatment-naive HIV-1-
infected adults. J Antimicrob Chemother. 2008;61(5):1145–1153.
43.  Stebbing J, Scourfield A, Koh G, Taylor C, Taylor S, Wilkins E, et al. 
A multicentre cohort experience with double-boosted protease inhibi-
tors. J Antimicrob Chemother. 2009;64(2):434–435.
44.  Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, 
Katlama C, et al. Efficacy and safety of ritonavir-boosted dual protease 
inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP 
ANRS 127 study. J Antimicrob Chemother. 2009;64(1):118–125.
45.  Dunning J, Nelson M. Novel strategies to treat antiretroviral-naive HIV-
infected patients. J Antimicrob Chemother. 2009;64(4):674–679.
46.  Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S,   
Mahanontharit A, et al. Pharmacokinetics of reduced-dose indinavir/
ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir 
Ther. 2005;10(2):301–307.
47.  Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J,   
Gorowara M, Phasomsap C, et al. Pharmacokinetics and 48 week 
efficacy of low-dose lopinavir/ritonavir in HIV-infected children.   
J Antimicrob Chemother. 2009;64(5):1080–1086.
48.  Laboratories. A. Kaletra (lopinavir/ritonavir) tablets and oral solu-
tion. Prescribing information. http://www.kaletra.com. Accessed 
1 October 2009.
49.  Oldfield V , Plosker GL. Lopinavir/ritonavir: a review of its use in the 
management of HIV infection. Drugs. 2006;66(9):1275–1299.
50.  Rosso R, Di Biagio A, Dentone C, Gattinara GC, Martino AM, 
Vigano A, et al. Lopinavir/ritonavir exposure in treatment-naive 
HIV-infected children following twice or once daily administration. J 
Antimicrob Chemother. 2006;57(6):1168–1171.
51.  van der Lee M, Verweel G, de Groot R, Burger D. Pharmacokinetics of 
a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. 
Antivir Ther. 2006;11(4):439–445.
52.  la Porte C, van Heeswijk R, Mitchell CD, Zhang G, Parker J,   
Rongkavilit C. Pharmacokinetics and tolerability of once- versus twice-
daily lopinavir/ritonavir treatment in HIV-1-infected children. Antivir 
Ther. 2009;14(4):603–606.
53.  van der Flier M, Verweel G, van der Knaap LC, van Jaarsveld P, 
  Driessen GJ, van der Lee M, et al. Pharmacokinetics of lopinavir in 
HIV type-1-infected children taking the new tablet formulation once 
daily. Antivir Ther. 2008;13(8):1087–1090.
54.  Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, 
Pancharoen C, et al. Pharmacokinetics and 24-week efficacy/safety of 
dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pre-treated 
children. Pediatr Infect Dis J. 2005;24(10):874–879.
55.  Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, 
Lumbiganon P, et al. Double boosted protease inhibitors, saquinavir, 
and lopinavir/ritonavir, in nucleoside pre-treated children at 48 weeks. 
Pediatr Infect Dis J. 2008;27(7):623–628.
56.  Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, 
Puthanakit T, et al. Safety and efficacy of a double-boosted protease 
inhibitor combination, saquinavir and lopinavir/ritonavir, in pre-treated 
children at 96 weeks. Antivir Ther. 2009;14(2):241–248.
57.  Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, 
Worrell C, et al. Pharmacokinetics of high-dose lopinavir-ritonavir with 
and without saquinavir or nonnucleoside reverse transcriptase inhibitors 
in human immunodeficiency virus-infected pediatric and adolescent 
patients previously treated with protease inhibitors. Antimicrob Agents 
Chemother. 2008;52(9):3276–3283.